Enveric Biosciences reported a net loss of $3.0 million for the second quarter ended June 30, 2026, with a basic and diluted loss per share of $0.76, compared to a net loss of $2.5 million in the prior year period. The company raised approximately $5.0 million through an at-the-market private placement and an additional $1.5 million from warrant exercises, bringing cash-on-hand to $8.3 million as of June 30, 2026. Development highlights include advancing IND-enabling studies for its lead candidate EB-003, reporting non-hallucinogenic profile data in preclinical assays, and securing U.S. patents for its EVM301 Series while receiving a Notice of Allowance for the EVM401 Series. Enveric Biosciences is a biotechnology company focused on developing next-generation neuroplastogenic small molecules to treat psychiatric and neurological disorders.

Enveric Biosciences, Inc. filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock under its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. The company has previously sold an aggregate of $4,483,711.04 through this agreement. Enveric Biosciences, Inc. is a biotechnology company focused on developing novel drug delivery technologies and therapeutics.

Enveric Biosciences, Inc. released an Investor Presentation for the second quarter of 2026. The presentation is intended for use in discussions with investors, analysts, lenders, and potential business partners. Enveric Biosciences, Inc. is a biotechnology company focused on developing drug delivery technologies and itself as a platform for a drug discovery platform.